Pulmocide Ltd

F2G Ltd encountered a significant setback as the US Food and Drug Administration gave the firm a complete response letter (CRL) for olorofim in invasive fungal infections. F2G said it is confident it

The end of each year brings a surge in venture capital funding announcements as biopharmaceutical companies and investors seek to close as many deals as possible before everyone takes off for the Dece

Having kicked off its late-stage clinical program for lead candidate opelconazole, the UK's Pulmocide Ltd has secured fresh funding to advance the antifungal for the treatment of invasive pulmonary

As venture capital financings for biopharmaceutical companies continues to head into record-breaking territory again in 2021, Illumina Ventures and Jeito Capital announced two new venture capital fund